Abliva AB ABLI

Overview

Abliva AB (publ), a pioneering clinical-stage biotech company, is at the forefront of developing innovative medicines aimed at the comprehensive treatment of primary mitochondrial diseases. Founded in 2000 and originally known as NeuroVive Pharmaceutical AB, the company underwent a rebranding to Abliva AB (publ) in May 2020, marking a new era in its quest to combat mitochondrial disorders. Located in Lund, Sweden, Abliva AB is devoted to addressing the unmet medical needs of patients suffering from these debilitating diseases. Through strategic collaboration with esteemed partners such as Isomerase, Yungjin Pharm, the University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments, Abliva AB is committed to advancing its robust pipeline of drug candidates towards clinical success, thus bringing hope to patients and their families worldwide.

Products and Services

Abliva AB's (publ) innovative portfolio includes several promising drug candidates at various stages of clinical development, specifically designed to target primary mitochondrial diseases:

• KL1333 - Currently in Phase 2/3 clinical trials, KL1333 represents a significant advancement in the chronic treatment of primary mitochondrial diseases. This novel compound is meticulously designed to modulate the NAD+/NADH ratio, a critical pathway affected in mitochondrial disorders, thereby offering the potential to improve energy metabolism in patients' cells.
• NV354 - NV354 is poised to enter clinical trials, focusing on the treatment of primary mitochondrial diseases with Complex I deficiency. Given the pivotal role of Complex I in cellular energy production, NV354 aims to supplement or bypass the dysfunctional pathway, thus potentially restoring normal energy production in affected cells.
• NeuroSTAT - In the Phase 1b/2a clinical study phase, NeuroSTAT is being explored for its potential in traumatic brain injury (TBI). By targeting mitochondrial dysfunction, a common consequence of TBI, NeuroSTAT offers a promising approach to mitigating the impact of brain injuries and improving outcomes for TBI patients.